A Phase 2b, Randomized, Double-Blind, Multi-center Study Comparing Cross-linked Polyelectrolyte (CLP) With Placebo in Heart Failure Subjects
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Talinexomer (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms STEPWISE
- Sponsors Sorbent Therapeutics
- 10 Jun 2017 Biomarkers information updated
- 15 May 2014 Status changed from recruiting to active, no longer recruiting as reported by a Sorbent Therapeutics media release.
- 30 Aug 2013 Planned End Date changed from 1 Oct 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.